{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T17:00:11Z","timestamp":1792515611497,"version":"4.5.0"},"reference-count":12,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,1,8]],"date-time":"2024-01-08T00:00:00Z","timestamp":1704672000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pediatr."],"abstract":"<jats:p>This study includes over 11.6M newborns screened (NBS) for Pompe Disease (PD) from 29 distinct universal screening programs across 8 countries and 4 continents. The birth prevalence of PD is 1:18,711, with no evidence of difference across populations of European, Latin American, or Asian ancestry, though differences may exist for PD subtypes. This study also compares these results, based on direct detection of disease and analyzed using a binomial method along with power analysis, with other methods for estimating the \u2018frequency\u2019 of rare genetic diseases (such as utilizing Hardy-Weinberg equilibrium on allele frequency and confidence interval analysis). This comparison demonstrates the implications of sample size and frames a discussion on its influence on the reliability of results when extrapolating to a population beyond the study dataset.<\/jats:p><jats:sec><jats:title>Objectives<\/jats:title><jats:p>Primary: Establish a new figure for prevalence at birth for Pompe disease by collecting and analyzing the largest relevant dataset to date and using that result to project population prevalence at birth in a novel way. Secondary: Compare these results to previous analyses to offer a framework for evaluating \u2018frequency\u2019 data that can be applied to other rare, genetic diseases, along with methods to assess quality of estimates.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fped.2023.1221140","type":"journal-article","created":{"date-parts":[[2024,1,8]],"date-time":"2024-01-08T05:57:05Z","timestamp":1704693425000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":29,"title":["An analysis of Pompe newborn screening data: a new prevalence at birth, insight and discussion"],"prefix":"10.3389","volume":"11","author":[{"given":"Ryan","family":"Colburn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Lapidus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,1,8]]},"reference":[{"key":"B1","year":""},{"key":"B2","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/j.ymgme.2010.08.001","article-title":"Differences in the predominance of lysosomal and autophagic pathologies between infants and adults with Pompe disease: implications for therapy","volume":"101","author":"Raben","year":"2010","journal-title":"Mol Genet Metab"},{"key":"B3","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.ymgme.2017.09.008","article-title":"Insight into the phenotype of infants with Pompe disease identified by newborn screening with the common c.-32-13T>G \u201clate-onset\u201d GAA variant","volume":"122","author":"Rairikar","year":"2017","journal-title":"Mol Genet Metab"},{"key":"B4","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.ymgme.2022.01.003","article-title":"Early clinical phenotype of late onset Pompe disease: lessons learned from newborn screening","volume":"135","author":"Huggins","year":"2022","journal-title":"Mol Genet Metab"},{"key":"B5","author":"Pillai","year":""},{"key":"B6","doi-asserted-by":"crossref","DOI":"10.1007\/978-90-481-9485-8_1","article-title":"Rare diseases\u2014avoiding misperceptions and establishing realities: the need for reliable epidemiological data","volume-title":"Rare diseases epidemiology. Advances in experimental medicine and biology","author":"Groft","year":"2010"},{"key":"B7","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1002\/(sici)1096-8628(19980827)79:1%3C69::aid-ajmg16%3E3.0.co;2-k","article-title":"Carrier frequency for glycogen storage disease type II in New York and estimates of affected individuals born with the disease","volume":"79","author":"Martiniuk","year":"1998","journal-title":"Am J Med Genet"},{"key":"B8","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1038\/sj.ejhg.5200367","article-title":"Frequency of glycogen storage disease type II in The Netherlands: implications for diagnosis and genetic counselling","volume":"7","author":"Ausems","year":"1999","journal-title":"Eur J Hum Genet"},{"key":"B9","doi-asserted-by":"publisher","first-page":"100734","DOI":"10.1016\/j.ymgmr.2021.100734","article-title":"Carrier frequency and predicted genetic prevalence of Pompe disease based on a general population database","volume":"27","author":"Park","year":"2021","journal-title":"Mol Genet Metab Rep"},{"key":"B10","year":""},{"key":"B11","doi-asserted-by":"publisher","first-page":"2146","DOI":"10.1002\/humu.23878","article-title":"GAA variants and phenotypes among 1,079 patients with Pompe disease: data from the Pompe registry","volume":"40","author":"Reuser","year":"2019","journal-title":"Hum Mutat"},{"key":"B12","doi-asserted-by":"publisher","first-page":"100929","DOI":"10.1016\/j.ymgmr.2022.100929","article-title":"Newborn screening for Pompe disease in Italy: long-term results and future challenges","volume":"33","author":"Gragnaniello","year":"2022","journal-title":"Mol Genet Metab Rep"}],"container-title":["Frontiers in Pediatrics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2023.1221140\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,11]],"date-time":"2024-01-11T16:49:12Z","timestamp":1704991752000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2023.1221140\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,8]]},"references-count":12,"alternative-id":["10.3389\/fped.2023.1221140"],"URL":"https:\/\/doi.org\/10.3389\/fped.2023.1221140","relation":{},"ISSN":["2296-2360"],"issn-type":[{"value":"2296-2360","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,8]]},"article-number":"1221140"}}